Archives
-
WYE-354: A Source-Bounded mTOR Overview
2026-10-18
APExBIO describes WYE-354 as a selective, ATP-competitive mTOR kinase inhibitor that affects both mTORC1- and mTORC2-associated signaling. The available product information reports biochemical potency, phosphoprotein readouts, cellular phenotypes, and one xenograft observation, but it does not provide a matched primary paper, complete study methods, statistical detail, or independent validation.
-
NB-598 Hydrochloride: Evidence Boundaries
2026-10-17
The available source documents identify NB-598 hydrochloride as an APExBIO product, SKU A3646, but provide no identity-matched research paper, target annotation, assay description, mechanism, or outcome data. The defensible scientific interpretation is therefore limited to catalog-level identity and to explaining why product naming cannot establish biological activity, selectivity, or measurement meaning.
-
HyperPac Gravity Chromatography Column: Evidence Scope
2026-10-16
The HyperPac Gravity Chromatography Column, 60 mL, is documented by APExBIO as an empty UHMWPE column for gravity-driven separations. Its reported dimensions, sieve plates, and material properties define a vessel and packing-retention format, not a validated purification performance claim. No identity-matched research evidence or comparative outcome data were provided.
-
CNQX and Chemerin-Driven Sympathetic Signaling
2026-10-16
A source-grounded analysis of how CNQX was used as a pharmacological comparator in a 2024 rat study of chemerin signaling, and why the findings support downstream NMDA-receptor involvement without establishing that AMPA or kainate receptors are biologically irrelevant.
-
Lisinopril Dihydrate: Mechanism and Evidence
2026-10-15
The APExBIO product page identifies Lisinopril dihydrate (SKU B3290) as a dihydrate form of the ACE inhibitor lisinopril and reports an IC50 of 4.7 nM. It also describes downstream effects on ACE activity, renin, angiotensin II, aldosterone, blood pressure, and heart rate. These statements provide a product-level mechanism overview, but no identity-matched research paper, independent validation, comparator data, model details, effect sizes, or uncertainty estimates are available in the supplied evidence.
-
SU 5402: Mechanism, Identity, and Evidence
2026-10-15
APExBIO identifies SU 5402, also written SU-5402, as a small-molecule inhibitor reported to act across VEGFR2, FGFR1, PDGFRβ, and EGFR. This editorial distinguishes catalog-level claims from identity-matched research evidence and explains the interpretive limits of kinase, phospho-signaling, cell-cycle, apoptosis, and tumor-model readouts.
-
Fluoxetine HCl: Mechanism and Evidence Boundaries
2026-10-14
The APExBIO product description identifies Fluoxetine HCl as an SSRI and reports transporter, 5-HT2C, and neurobiological research contexts. Because no identity-matched primary paper is available here, these claims support a conceptual interpretation rather than conclusions about efficacy, assay performance, or causal mechanisms.
-
Cyclopamine: Scope and Evidence Boundaries
2026-10-14
Cyclopamine is a Smoothened-directed Hedgehog signaling inhibitor used as a research tool in cancer and developmental biology. The supplied evidence supports pathway-focused, model-specific interpretations, but does not establish universal anticancer activity, clinical efficacy, or a quantitative human safety profile.
-
Potato Virus X as a Nucleic Acid Delivery Platform
2026-10-13
A 2025 Scientific Reports study presents potato virus X coat-protein assemblies as a modular platform for packaging linear and circular RNA. The reported results show tunable particle architectures and reporter-protein expression in eukaryotic cells, but the evidence remains an early proof of concept. The study does not, on the supplied record, establish clinical efficacy, tissue-specific delivery, long-term safety, or superiority over established delivery systems.
-
Thiazovivin: Identity and Evidence Scope
2026-10-13
Thiazovivin is cataloged by APExBIO as a small-molecule ROCK inhibitor associated with conceptual research on induced pluripotent stem cell generation and human embryonic stem cell survival. Because no matched paper is available, these applications remain supplier-described scope rather than independently assessed findings.
-
Angiotensin I/II (1-5): Evidence Scope
2026-10-12
A source-limited overview of the documented identity and conceptual research scope of Angiotensin I/II (1-5), with clear boundaries around unverified biological claims and the absence of matched literature.
-
Mestranol and Reversible Lysosomal Stress in Microglia
2026-10-12
A 2026 zebrafish study reports that mestranol produces a reversible lysosomal storage–like state in microglia. The evidence links microglial hypertrophy and impaired intracellular cargo digestion with altered lysosomal and immune transcriptional programs, while distinguishing these effects from neuronal apoptosis. The findings are compelling within the zebrafish model but do not establish a human disease mechanism or prove that mestranol causes inherited lysosomal storage disease.
-
Tetrandrine and the Limits of NSP15 Evidence
2026-10-11
The cited 2021 study provides computational evidence for thymopentin and oleuropein as predicted SARS-CoV-2 NSP15 binders, not evidence that Tetrandrine inhibits NSP15 or SARS-CoV-2. Supplier descriptions of Tetrandrine’s ion-channel and inflammation-related research uses cannot substitute for target-specific biochemical, cellular, or clinical validation.
-
mCherry mRNA as a Reporter of Delivery Biology
2026-10-10
Learn how mCherry mRNA can function as more than a fluorescent label: it can help separate delivery, translation, persistence, and cell-state effects. This evidence-centered guide examines Cap 1 chemistry, modified nucleotides, and the relevance of recent lipid nanoparticle research.
-
Ibrexafungerp Against Resistant Candida auris
2026-10-09
Wiederhold et al. examined ibrexafungerp, also known as MK 3118, against fluconazole-resistant Candida auris using complementary in vitro susceptibility data and a delayed-treatment murine model. The study supports further evaluation of an orally administered glucan-synthase inhibitor, while its single-isolate animal model limits direct clinical extrapolation.